Φορτώνει......
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F(2α) receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrate...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Ophthalmol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079698/ https://ncbi.nlm.nih.gov/pubmed/27799730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S103985 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|